In Reply Dr Kashoki and colleagues provide helpful insight about progress made in decreasing the backlog of postmarketing studies from September 2007, when the FDAAA was enacted. Despite this, our research aim was broader: to examine the annual number of postmarketing studies, both required and voluntary, in each status category and the trends since the law’s enactment. The initial backlog of studies is an important part of the picture. However, since September 2007, many new postmarketing studies have been required by the FDA or voluntarily established. The data in the Agency’s Federal Register notices, upon which our analysis relied, include both the backlogged and new studies.1
Fain K, Alexander GC. Drug Postmarketing Studies—Reply. JAMA. 2013;310(22):2459–2460. doi:10.1001/jama.2013.278904
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: